NovoCure Limited Share Price

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 21:00:00 19/07/2024 BST 5-day change 1st Jan Change
18.4 USD -0.43% Intraday chart for NovoCure Limited +2.34% +23.24%
Sales 2024 * 553M 42.8B Sales 2025 * 592M 45.82B Capitalization 1.98B 153B
Net income 2024 * -175M -13.54B Net income 2025 * -188M -14.55B EV / Sales 2024 * 3.42 x
Net cash position 2024 * 90.5M 7B Net Debt 2025 * 59M 4.57B EV / Sales 2025 * 3.44 x
P/E ratio 2024 *
-11.4 x
P/E ratio 2025 *
-10.8 x
Employees 1,453
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.73%
More Fundamentals * Estimated data
Dynamic Chart
1 day-0.43%
1 week+2.34%
Current month+7.41%
1 month-3.51%
3 months+52.19%
6 months+31.62%
Current year+23.24%
More quotes
1 week
17.88
Extreme 17.88
19.37
1 month
15.85
Extreme 15.85
19.37
Current year
11.70
Extreme 11.7
24.74
1 year
10.87
Extreme 10.87
41.51
3 years
10.87
Extreme 10.87
190.83
5 years
10.87
Extreme 10.87
232.76
10 years
5.95
Extreme 5.95
232.76
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 31/12/01
Director of Finance/CFO 45 31/05/14
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chairman 61 31/12/03
Director/Board Member 63 04/08/11
Director/Board Member 67 30/05/18
More insiders
Date Price Change Volume
19/07/24 18.4 -0.43% 685,583
18/07/24 18.48 -3.30% 794,051
17/07/24 19.11 -0.88% 914,056
16/07/24 19.28 +7.17% 1,081,517
15/07/24 17.99 +0.06% 962,604

Delayed Quote Nasdaq, July 19, 2024 at 09:00 pm

More quotes
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
18.4 USD
Average target price
27.14 USD
Spread / Average Target
+47.52%
Consensus